CTOs on the Move

WithMe Health

www.withmehealth.com

 
WithMe Health replaces an employer`s pharmacy benefit manager (PBM) with a personalized medication guidance solution that greatly improves on and expands the scope of services available in the market today. Our modern technology and rich datasets allow consistent application of proven science to create individualized medication experiences for employees and their families that are proactive, adaptive, convenient and engaging. With an innovative, outcomes-oriented business model that aligns interests across the pharmaceutical value chain, WithMe Health optimizes health outcomes and value while substantially reducing costs for employers.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

WithMe Health raised $20M on 11/24/2020

Similar Companies

RRS Ohio Drug & Alcohol Counseling

RRS Ohio is a company that offers effective outpatient, individualized addiction treatment and substance abuse disorder treatment. They provide a neutral safe space for individuals to heal, energize, and become aware of their inner strengths.

United Home Care

United Home Care is a Minden, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EMR 4 DOCTORS

EMR 4 DOCTORS is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nivalis Therapeutics

Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.